Stimulatory effects of CpG ollgodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice

Keyphrases

• Cell-based 100%
• Colon Cancer 100%
• Dendritic Cells 100%
• CpG ODN 100%
• Stimulatory Effect 100%
• HLA Transgenic Mice 100%
• Tumor 50%
• Tumor-free Survival 50%
• HLA-A2 50%
• Tumor Regression 50%
• Colon Adenocarcinoma 50%
• Clinically Significant 25%
• Transgenic 25%
• Combination Therapy 25%
• T Cells 25%
• Vaccination 25%
• Tumor Growth 25%
• Mouse Model 25%
• Vaccination Strategy 25%
• Murine Model 25%
• Tumor Antigen 25%
• Guanine 25%
• T Cell Response 25%
• Systemic Administration 25%
• Tumor Burden 25%
• Cytosine 25%
• Long-term Survival 25%
• Rechallenge 25%
• Athymic nude Mice 25%
• CTL Response 25%
• Tumor-free 25%
• Therapeutic Setting 25%
• CpG Motif 25%
• Combined Vaccination 25%
• Immunostimulatory DNA 25%
• Antitumor T Cells 25%
• Large Tumor 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Transgenic Mouse 100%
• Colon Carcinoma 100%
• HLA A2 Antigen 100%
• Neoplasm 100%
• Immunotherapy 100%
• CpG Oligodeoxynucleotide 80%
• Antigen 60%
• Tumor Regression 40%
• Vaccination 40%
• Mouse Model 20%
• Nude Mouse 20%
• Tumor Growth 20%
• Cytokine 20%
• Long Term Survival 20%
• Systemic Administration 20%
• Dendritic Cell Vaccine 20%
• Combination Therapy 20%
• Cytosine 20%
• Guanine 20%
• Adjuvant 20%
• Tumor Antigen 20%

Immunology and Microbiology

• Dendritic Cell 100%
• Colon 100%
• Transgenic Mouse 100%
• HLA A2 Antigen 100%
• Immunotherapy 100%
• CpG Oligodeoxynucleotide 80%
• Antigen 60%
• T Cell 40%
• Adjuvant 20%
• Mouse Model 20%
• Secretion (Process) 20%
• Transgenics 20%
• Nude Mouse 20%
• Tumor Volume 20%
• Long Term Survival 20%
• Dendritic Cell Vaccine 20%
• Cytokine 20%
• Tumor Antigen 20%